{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:05:52Z","timestamp":1785708352786,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.msard.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T22:32:26Z","timestamp":1491690746000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"C","title":["Tumefactive demyelinating lesions: A comprehensive review"],"prefix":"10.1016","volume":"14","author":[{"given":"Hussein","family":"Algahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Shirah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2017.04.003_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.msard.2015.07.013","article-title":"Neuro-oncology dilemma: tumour or tumefactive demyelinating lesion","volume":"4","author":"Abdoli","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2017.04.003_bib2","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1177\/1352458512438237","article-title":"Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study","volume":"18","author":"Altintas","year":"2012","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2017.04.003_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1212\/01.WNL.0000130357.51278.CF","article-title":"Tumefactive neuro-Behcet disease","volume":"63","author":"Bennett","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2017.04.003_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1352458507087135","article-title":"Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy","volume":"14","author":"Berger","year":"2008","journal-title":"Mult. Scler."},{"issue":"909","key":"10.1016\/j.msard.2017.04.003_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1259\/bjr\/85069069","article-title":"Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis","volume":"76","author":"Butteriss","year":"2003","journal-title":"Br. J. Radiol."},{"issue":"6","key":"10.1016\/j.msard.2017.04.003_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/030089160609200619","article-title":"Tumor-like multiple sclerosis: report of four cases and literature review","volume":"92","author":"Caroli","year":"2006","journal-title":"Tumori"},{"issue":"12","key":"10.1016\/j.msard.2017.04.003_bib7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e31824c46ad","article-title":"Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?","volume":"78","author":"Castrop","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2017.04.003_bib8","first-page":"1109","article-title":"Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions","volume":"22","author":"Cha","year":"2001","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"Suppl 4","key":"10.1016\/j.msard.2017.04.003_bib9","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1007\/s10072-004-0345-x","article-title":"Multiple sclerosis: pseudotumoral forms","volume":"25","author":"Comi","year":"2004","journal-title":"Neurol. Sci."},{"issue":"Suppl 4","key":"10.1016\/j.msard.2017.04.003_bib10","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1007\/s10072-004-0345-x","article-title":"Multiple sclerosis: pseudotumoral forms","volume":"25","author":"Comi","year":"2004","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2017.04.003_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00019052-200206000-00006","article-title":"Natural history of multiple sclerosis: implications for counselling and therapy","volume":"15","author":"Confavreux","year":"2002","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2017.04.003_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/0883073808324769","article-title":"Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal","volume":"24","author":"Dastgir","year":"2009","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.msard.2017.04.003_bib13","article-title":"Open-ring enhancement in pseudotumoral multiple sclerosis: important radiological aspect","volume":"2014","author":"De medeiros","year":"2014","journal-title":"Case Rep. Neurol. Med."},{"issue":"18","key":"10.1016\/j.msard.2017.04.003_bib14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/WNL.0000000000002084","article-title":"Extensive brain demyelinating lesions under natalizumab: the role of anti-natalizumab antibodies","volume":"85","author":"Debs","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2017.04.003_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1756285615594575","article-title":"Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment","volume":"8","author":"Faissner","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"10","key":"10.1016\/j.msard.2017.04.003_bib16","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.clineuro.2012.03.010","article-title":"Rituximab for tumefactive inflammatory demyelination: a case report","volume":"114","author":"Fan","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"3","key":"10.1016\/j.msard.2017.04.003_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11910-016-0626-9","article-title":"Tumefactive demyelinating lesions in multiple sclerosis and associated disorders","volume":"16","author":"Frederick","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"19","key":"10.1016\/j.msard.2017.04.003_bib18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1212\/WNL.0b013e3182735d24","article-title":"Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod","volume":"79","author":"Gross","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00415-010-5722-1","article-title":"Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumour","volume":"258","author":"H\u00e4ne","year":"2011","journal-title":"J. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2017.04.003_bib20","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1177\/0883073816664667","article-title":"Biopsy-Supported Tumefactive Demyelination of the Central Nervous System in Children","volume":"31","author":"Hanumanthe","year":"2016","journal-title":"J. Child Neurol."},{"issue":"9","key":"10.1016\/j.msard.2017.04.003_bib21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/jnnp-2012-304498","article-title":"Tumefactive demyelination: an approach to diagnosis and management","volume":"84","author":"Hardy","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"8","key":"10.1016\/j.msard.2017.04.003_bib22","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00415-008-0883-x","article-title":"Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology","volume":"255","author":"Haupts","year":"2008","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2017.04.003_bib23","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00415-008-0883-x","article-title":"Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology","volume":"255","author":"Haupts","year":"2008","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2017.04.003_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-009-0178-z","article-title":"The pathological spectrum of CNS inflammatory demyelinating diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Semin Immunopathol."},{"issue":"9","key":"10.1016\/j.msard.2017.04.003_bib25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.50.4295","article-title":"Repeated non-enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder","volume":"50","author":"Ikeda","year":"2011","journal-title":"Intern Med."},{"issue":"9","key":"10.1016\/j.msard.2017.04.003_bib26","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/archneur.62.9.1466","article-title":"Demyelinating pseudotumor","volume":"62","author":"Jaffe","year":"2005","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2017.04.003_bib27","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod","volume":"18","author":"Jander","year":"2012","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2017.04.003_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/hupa.2003.34","article-title":"In situ cytokine immune responses in acute disseminated encephalomyelitis: insights into pathophysiologic mechanisms","volume":"34","author":"Kadhim","year":"2003","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.msard.2017.04.003_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcm.2010.08.002","article-title":"Tumefactive multiple sclerosis: an uncommon diagnostic challenge","volume":"10","author":"Kaeser","year":"2011","journal-title":"J. Chiropr. Med."},{"key":"10.1016\/j.msard.2017.04.003_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48\u201349","author":"Karussis","year":"2014","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.msard.2017.04.003_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410330105","article-title":"Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients","volume":"33","author":"Kepes","year":"1993","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2017.04.003_bib32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e31820c30af","article-title":"Tumefactive demyelination, an uncommon form of tacrolimus neurotoxicity","volume":"76","author":"Kim","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib33","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/j.1552-6569.2010.00502.x","article-title":"Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm","volume":"21","author":"Kiriyama","year":"2011","journal-title":"J. Neuroimaging."},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3174\/ajnr.A3677","article-title":"Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions","volume":"35","author":"Lu","year":"2014","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"Pt 7","key":"10.1016\/j.msard.2017.04.003_bib35","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awn098","article-title":"Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis","volume":"131","author":"Lucchinetti","year":"2008","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2017.04.003_bib37","unstructured":"Nealon N., 2011 October. Severe multiple sclerosis relapse on Fingolimod. Risk management for disease-modifying treatments 1. In: Proceedings 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple SclerosisAmsterdam, The Netherlands."},{"issue":"7","key":"10.1016\/j.msard.2017.04.003_bib38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000082170.18782.97","article-title":"Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange","volume":"61","author":"Paus","year":"2003","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.msard.2017.04.003_bib39","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","article-title":"Tumefactive MS lesions under fingolimod: a case report and literature review","volume":"81","author":"Pilz","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1941874412466873","article-title":"Fulminant demyelinating diseases","volume":"3","author":"Rahmlow","year":"2013","journal-title":"Neurohospitalist"},{"issue":"4","key":"10.1016\/j.msard.2017.04.003_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5414\/NP300201","article-title":"Tumefactive demyelination and glioblastoma: a rare collision lesion","volume":"30","author":"Roemer","year":"2011","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.msard.2017.04.003_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215596","article-title":"Severe tumefactive rebound of multiple sclerosis following fingolimod cessation","volume":"2016","author":"Salam","year":"2016","journal-title":"BMJ Case Rep."},{"issue":"10","key":"10.1016\/j.msard.2017.04.003_bib44","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3174\/ajnr.A1204","article-title":"Primary Sj\u00f6gren Syndrome with tumefactive central nervous system involvement","volume":"29","author":"Sanahuja","year":"2008","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"3","key":"10.1016\/j.msard.2017.04.003_bib45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","article-title":"A systematic approach to the diagnosis of suspected central nervous system lymphoma","volume":"70","author":"Scott","year":"2013","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2017.04.003_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-007-0754-x","article-title":"MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings","volume":"255","author":"Seewann","year":"2008","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2017.04.003_bib47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/1352458511429012","article-title":"Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response","volume":"18","author":"Seifert","year":"2012","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2017.04.003_bib48","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/jnnp-2013-305456","article-title":"Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange","volume":"84","author":"Sempere","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib49","first-page":"455","article-title":"Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines","volume":"27","author":"Simon","year":"2006","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"8","key":"10.1016\/j.msard.2017.04.003_bib50","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajem.2014.01.026","article-title":"It is not a tumor: a rare case of tumefactive multiple sclerosis","volume":"32","author":"Smith","year":"2014","journal-title":"Am. J. Emerg. Med."},{"issue":"10","key":"10.1016\/j.msard.2017.04.003_bib51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.0b013e3182840be3","article-title":"Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies","volume":"80","author":"Svenningsson","year":"2013","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.04.003_bib52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2010.01.001","article-title":"A giant MS plaque mimicking PML during natalizumab treatment","volume":"291","author":"Twyman","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2017.04.003_bib53","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1086\/656812","article-title":"Tumefactive demyelination-an unusual neurological presentation of HIV","volume":"51","author":"Uriel","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2017.04.003_bib54","article-title":"Tumefactive demyelination associated with systemic lupus erythematosus","volume":"2012","author":"Verma","year":"2012","journal-title":"BMJ Case Rep."},{"issue":"19","key":"10.1016\/j.msard.2017.04.003_bib55","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1212\/WNL.0b013e3182735cb3","article-title":"Tumefactive multiple sclerosis lesions under fingolimod treatment","volume":"79","author":"Visser","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2017.04.003_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-013-6918-y","article-title":"Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis","volume":"260","author":"Wallner-blazek","year":"2013","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.04.003_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2010.06.030","article-title":"Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event","volume":"297","author":"Wattamwar","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2017.04.003_bib58","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10143-009-0185-5","article-title":"Tumefactive demyelinating lesions: nine cases and a review of the literature","volume":"32","author":"Xia","year":"2009","journal-title":"Neurosurg. Rev."},{"issue":"2","key":"10.1016\/j.msard.2017.04.003_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10143-009-0185-5","article-title":"Tumefactive demyelinating lesions: nine cases and a review of the literature","volume":"32","author":"Xia","year":"2009","journal-title":"Neurosurg. Rev."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481730072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481730072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:39:48Z","timestamp":1761899988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481730072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":60,"alternative-id":["S221103481730072X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.04.003","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumefactive demyelinating lesions: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}